Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 5/2017

Open Access 01-05-2017 | Gastrointestinal Cancers (J Meyer, Section Editor)

Immunotherapy for Esophageal Squamous Cell Carcinoma

Authors: Takashi Kojima, Toshihiko Doi

Published in: Current Oncology Reports | Issue 5/2017

Login to get access

Abstract

Esophageal squamous cell carcinoma have been frustrating to treat, with slow progress made on extending survival. Immunotherapy targeting immune checkpoints, T cells, and infiltrating lymphocytes has shown promise in early studies. The efficacy of pembrolizumab and nivolumab is encouraging. Anti-chemokine receptors and oncolytic viruses are also making headway against these stubborn tumors; improved results when immune checkpoint inhibitors are combined with radiation therapy are eagerly anticipated. Adoptive T cell therapy and vaccines are also under development. The importance of a multidisciplinary approach cannot be emphasized enough.
Literature
1.
Wang K, et al. Comprehensive genomic profiling of advanced esophageal squamous cell carcinomas and esophageal adenocarcinomas reveals similarities and differences. Oncologist. 2015;20(10):1132–9.CrossRefPubMedPubMedCentral
2.
Sawada G, et al. Genomic landscape of esophageal squamous cell carcinoma in a Japanese population. Gastroenterology. 2016;150(5):1171–82.CrossRefPubMed
3.
Fuchs CS, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9.CrossRefPubMed
4.
Wilke H, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35.CrossRefPubMed
5.
Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.CrossRefPubMed
6.
Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed
7.
Bagnardi V, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer. 2015;112(3):580–93.CrossRefPubMed
8.
9.
Lin, D.C., et al., Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet, 2014.
10.
11.
Iizuka T, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol. 1992;22(3):172–6.PubMed
12.
Levard H, et al. 5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research. Eur J Surg. 1998;164(11):849–57.CrossRefPubMed
13.
Kato K, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol. 2011;67(6):1265–72.CrossRefPubMed
14.
Muro K, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15(6):955–9.CrossRefPubMed
15.
Crosby T, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013;14(7):627–37.CrossRefPubMed
16.
Dutton SJ, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. 2014;15(8):894–904.CrossRefPubMed
17.
Moehler M, et al. Immunotherapy in gastrointestinal cancer: recent results, current studies and future perspectives. Eur J Cancer. 2016;59:160–70.CrossRefPubMed
18.
Chen L, et al. B7-H1 expression associates with tumor invasion and predicts patient’s survival in human esophageal cancer. Int J Clin Exp Pathol. 2014;7(9):6015–23.PubMedPubMedCentral
19.
Hatogai, K., et al., Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma. Oncotarget, 2016.
20.
Chen, K., et al., Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget, 2016.
21.
Ostrand-Rosenberg S, Horn LA, Haile ST. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol. 2014;193(8):3835–41.CrossRefPubMedPubMedCentral
22.
Rizvi NA, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8.CrossRefPubMedPubMedCentral
23.
24.
Seiwert TY, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–65.CrossRefPubMed
25.
•• Doi T, Sarina Anne Piha-Paul, Shadia Ibrahim Jalal, Hieu Mai-Dang, Sammy Yuan, Minori Koshiji, Ildiko Csiki, Jaafar Bennouna, Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal carcinoma: preliminary results from KEYNOTE-028. J Clin Oncol, 2015. 33(suppl; abstr 4010). Pembrolizumab, an anti-PD-1 antibody, has an acceptable safety profile and provides promising antitumor activity in pts with heavily pretreated, PD-L1+ advanced esophageal carcinoma.
26.
•• Doi T, Sarina Anne Piha-Paul, Shadia Ibrahim Jalal, Hieu Mai-Dang, Sanatan Saraf, Minori Koshiji, Ildiko Csiki, Jaafar Bennouna, Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475). J Clin Oncol, 2016. 34(suppl 4S; abstr 7). In this phase Ib study of pembrolizumab for esophageal cancer, the 6-gene interferon-inflammatory gene signature scores were evaluated along with PFS. Pattern of response with an immune gene expression signature score was similar to that found in head and neck and gastric cancer.
27.
• Kojima T, H H, Kensei Yamaguchi, Shuichi Hironaka, Satoru Iwasa, Ken Kato, Takahiro Tsushima, Hirofumi Yasui, Takashi Ura, Kei Muro, Taroh Satoh, Yuichiro Doki, Atsushi Ohtsu, Yasuo Hamamoto, Yuko Kitagawa, Phase II study of nivolumab (ONO-4538/BMS-936558) in patients with esophageal cancer: preliminary report of overall survival. J Clin Oncol, 2016. 34(suppl 4S; abstr TPS175). Nivolumab, an anti-PD-1 antibody, has meaningful activity and a manageable safety profile in pretreated esophageal cancer.
28.
• Kurose K, et al. Phase Ia study of FoxP3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients. Clin Cancer Res. 2015;21(19):4327–36. KW-0761 in patients with advanced solid tumors in a dose range between 0.1 and 1.0 mg/kg was safe and well tolerated. This study was conducted in 7 lung and 3 esophageal cancer patients. CrossRefPubMed
29.
30.
Salama AK, Postow MA, Salama JK. Irradiation and immunotherapy: from concept to the clinic. Cancer. 2016;122(11):1659–71.CrossRefPubMed
31.
32.
33.
34.
35.
36.
Kakimi K, et al. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int J Cancer. 2011;129(12):2836–46.CrossRefPubMed
37.
Kageyama S, et al. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. J Transl Med. 2013;11:246.CrossRefPubMedPubMedCentral
38.
Iinuma H, et al. Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J Transl Med. 2014;12:84.CrossRefPubMedPubMedCentral
39.
Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev. 2016;30(3):157–67.CrossRefPubMed
40.
Robbins PF, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21(5):1019–27.CrossRefPubMed
41.
Kageyama S, et al. Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer. Clin Cancer Res. 2015;21(10):2268–77. A first-in-man clinical trial of TCR gene-transduced T-cell transfer in patients with recurrent MAGE-A4-expressing esophageal cancer.
42.
43.
Andtbacka RH, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8.CrossRefPubMed
44.
45.
46.
Georgina V. Long, R.D., Antoni Ribas, Igor Puzanov, Ari VanderWalde, Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. J Clin Oncol, 2016. 34(suppl; abstr 9568).
47.
Puzanov I, M M., Andtbacka R, Minor D, Hamid, Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol, 2014. 32(suppl; abstr 9029).
48.
• Tanabe S, H T., Shunsuke Kagawa, Kazuhiro Noma, Kiyoto Takehara, Takeshi Koujima, Hajime Kashima, Takuya Kato, Shinji Kuroda, Satoru Kikuchi, Yasuhiro Shirakawa, Toshiyoshi Fujiwara, Phase I/II trial of endoscopic intratumoral administration of OBP-301, a novel telomerase-specific oncolytic virus, with radiation in elderly esophageal cancer patients. Cancer Res, 2015. 75(15 Suppl):Abstract nr CT123. Endoscopic oncolytic virus injection in combination with locoregional radiotherapy was feasible and well tolerated in patients with ESCC .
49.
Wolchok JD, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33.CrossRefPubMed
Metadata
Title
Immunotherapy for Esophageal Squamous Cell Carcinoma
Authors
Takashi Kojima
Toshihiko Doi
Publication date
01-05-2017
Publisher
Springer US
Published in
Current Oncology Reports / Issue 5/2017
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-017-0590-9

Other articles of this Issue 5/2017

Current Oncology Reports 5/2017 Go to the issue

Breast Cancer (B Overmoyer, Section Editor)

The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer

Lymphomas (MR Smith, Section Editor)

Optimal Therapy for Early-Stage Hodgkin’s Lymphoma: Risk Adapting, Response Adapting, and Role of Radiotherapy

Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Emerging Variants of Castration-Resistant Prostate Cancer

Melanoma (RJ Sullivan, Section Editor)

Adjuvant Therapy for Melanoma

Leukemia (A Aguayo, Section Editor)

Philadelphia-Like Acute Lymphoblastic Leukemia in Adults
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits